| Company Name: |
Jinan Jiuli Biotechnology Co. , Ltd. Gold
|
| Tel: |
15865264761 |
| Email: |
486064515@qq.com |
| Products Intro: |
Product Name:BMS-986365;CC-94676
CAS:2446928-30-7
Purity:98% Package:500mg；1g；5g
|
| Company Name: |
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
|
| Tel: |
17702719238 18971495150; |
| Email: |
sales@sun-shinechem.com |
| Products Intro: |
Product Name:BMS-986365
CAS:2446928-30-7
Purity:98% HPLC Package:50.0mg;100.0mg; 200.0mg;500mg;1g;5g; 10g
|
|
| | CC-94676 Basic information |
| Product Name: | CC-94676 | | Synonyms: | CC-94676;2-((R)-4-(2-(4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-ethylphenoxy)ethyl)-2-methylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide;1-Piperazineacetamide, 4-[2-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-ethylphenoxy]ethyl]-N-[3-[(2,6-dioxo-3-piperidinyl)amino]phenyl]-2-methyl-, (2R)-;(2R)-4-[2-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-ethylphenoxy]ethyl]-N-[3-[(2,6-dioxo-3-piperidinyl)amino]phenyl]-2-methyl-1-piperazineacetamide;BMS-986365 | | CAS: | 2446928-30-7 | | MF: | C41H45F3N8O5S | | MW: | 818.91 | | EINECS: | | | Product Categories: | | | Mol File: | 2446928-30-7.mol |  |
| | CC-94676 Chemical Properties |
| density | 1.41±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 11.06±0.40(predicted) | | form | Solid | | color | White to off-white | | InChIKey | YUVGVJYLOFTILT-NHYGQJMQSA-N | | SMILES | S=C1N(C2C=CC(=C(C=2)CC)OCCN2CCN([C@@H](C2)C)CC(=O)NC2C=CC=C(C=2)NC2CCC(NC2=O)=O)C(C(N1C1C=CC(=C(C=1)C(F)(F)F)C#N)=O)(C)C |
| | CC-94676 Usage And Synthesis |
| Uses | BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader, capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. (Blue: HY-W247437; Black: linker (HY-W126831); Pink: HY-168697)[1][2][3][4][5]. | | References | [1] Xu S, et al. Abstract ND02: Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer[J]. Cancer Research, 2024, 84(7_Supplement): ND02-ND02.
[2] Rathkopf DE, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2024 Sep 16:S0923-7534(24)04001-8. DOI:10.1016/j.annonc.2024.09.005
[3] Poh A. A Dual AR Degrader–Inhibitor for Prostate Cancer[J]. 2024.
[4] Rathkopf D E, et al. First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)[J]. 2024.
[5] Scott JS, et al. Property-based optimisation of PROTACs. RSC Med Chem. 2024 Nov 7. DOI:10.1039/d4md00769g |
| | CC-94676 Preparation Products And Raw materials |
|